HomeIndustriesHealthcareAbbvie (ABBV) To Acquire Immunogen (IMGN)

Abbvie (ABBV) To Acquire Immunogen (IMGN)

Abbvie (ABBV) is to acquire Immunogen (IMGN). Jenny Horne discusses this Biotech deal as the transaction values IMGN at $10.1B. ABBV is to acquire outstanding shares of IMGN for $31.26 per share in cash. This deal is expected to close in the middle of 2024 and the proposed transaction is expected to be accretive to EPS beginning in 2027. Tune in to find out more about the stock market today.

Market On Close

30 Nov 2023

SHARE

ON AIR
3:00 am
Fast Market
replay
12:00 am
Market Overtime
REPLAY
12:30 am
Market On Close
REPLAY
education
2:00 am
Your First Trade
REPLAY
education
2:30 am
Your First Trade
REPLAY
ON AIR
3:00 am
Fast Market
REPLAY
4:00 am
Next Gen Investing
REPLAY
5:00 am
Market Overtime
REPLAY
5:30 am
The Wrap
REPLAY
7:00 am
Morning Movers
8:00 am
Opening Bell With Nicole Petallides
9:00 am
Morning Trade Live
10:00 am
Trading 360
11:00 am
Fast Market
12:00 pm
Next Gen Investing
1:00 pm
The Watch List
2:00 pm
Market On Close
3:30 pm
Market Overtime
REPLAY
4:00 pm
Fast Market
REPLAY
5:00 pm
Next Gen Investing
REPLAY
6:00 pm
The Wrap
REPLAY
education
7:30 pm
Liz Ann Live
REPLAY
8:00 pm
Market Overtime
REPLAY
8:30 pm
Market On Close
REPLAY
education
10:00 pm
Liz Ann Live
REPLAY
10:30 pm
The Wrap
REPLAY

Schwab Network's Newsletters

Daily insights for every investor